Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uterine Cervical Neoplasms | 16 | 2023 | 2020 | 2.230 |
Why?
|
Genital Neoplasms, Female | 4 | 2021 | 523 | 1.870 |
Why?
|
Uterine Cervical Dysplasia | 3 | 2023 | 387 | 1.670 |
Why?
|
Robotics | 4 | 2013 | 899 | 0.740 |
Why?
|
Endometrial Neoplasms | 6 | 2013 | 1353 | 0.690 |
Why?
|
Papillomavirus Infections | 2 | 2023 | 1587 | 0.620 |
Why?
|
Cryotherapy | 1 | 2018 | 155 | 0.610 |
Why?
|
Gynecology | 5 | 2021 | 513 | 0.610 |
Why?
|
Ovarian Neoplasms | 14 | 2023 | 4838 | 0.580 |
Why?
|
Developing Countries | 4 | 2018 | 2815 | 0.570 |
Why?
|
Laparoscopy | 5 | 2013 | 2151 | 0.540 |
Why?
|
Mentors | 1 | 2021 | 631 | 0.540 |
Why?
|
Fellowships and Scholarships | 2 | 2021 | 1076 | 0.530 |
Why?
|
Women's Health | 2 | 2023 | 2034 | 0.510 |
Why?
|
Adnexal Diseases | 1 | 2015 | 102 | 0.470 |
Why?
|
Urologic Neoplasms | 1 | 2018 | 318 | 0.460 |
Why?
|
Medical Oncology | 6 | 2021 | 2265 | 0.460 |
Why?
|
Marriage | 1 | 2014 | 339 | 0.440 |
Why?
|
Vulvar Neoplasms | 2 | 2022 | 272 | 0.400 |
Why?
|
Vulnerable Populations | 1 | 2016 | 687 | 0.380 |
Why?
|
Premenopause | 1 | 2015 | 1033 | 0.380 |
Why?
|
Pelvic Exenteration | 1 | 2010 | 22 | 0.370 |
Why?
|
Health Resources | 1 | 2016 | 911 | 0.350 |
Why?
|
Reproduction | 1 | 2014 | 668 | 0.350 |
Why?
|
Hysterectomy | 3 | 2010 | 927 | 0.310 |
Why?
|
Neoplasm Staging | 7 | 2023 | 11031 | 0.280 |
Why?
|
Pubic Symphysis | 1 | 2006 | 21 | 0.280 |
Why?
|
Vagina | 2 | 2009 | 825 | 0.250 |
Why?
|
Poverty | 1 | 2016 | 2660 | 0.240 |
Why?
|
Female | 49 | 2023 | 380194 | 0.240 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2023 | 59 | 0.230 |
Why?
|
Saphenous Vein | 1 | 2005 | 532 | 0.210 |
Why?
|
Cystadenocarcinoma, Serous | 2 | 2023 | 450 | 0.210 |
Why?
|
Osteomyelitis | 1 | 2006 | 402 | 0.200 |
Why?
|
Healthcare Disparities | 2 | 2016 | 3158 | 0.200 |
Why?
|
Genes, BRCA1 | 4 | 2016 | 781 | 0.190 |
Why?
|
Trophoblastic Tumor, Placental Site | 1 | 2000 | 14 | 0.180 |
Why?
|
Vaginal Smears | 1 | 2023 | 511 | 0.180 |
Why?
|
Obesity, Abdominal | 1 | 2023 | 361 | 0.180 |
Why?
|
Health Priorities | 1 | 2023 | 380 | 0.180 |
Why?
|
Mass Screening | 1 | 2015 | 5255 | 0.170 |
Why?
|
Education, Distance | 1 | 2022 | 251 | 0.170 |
Why?
|
Feasibility Studies | 2 | 2019 | 5078 | 0.160 |
Why?
|
Genomics | 1 | 2014 | 5720 | 0.160 |
Why?
|
Uganda | 1 | 2023 | 1243 | 0.160 |
Why?
|
Humans | 50 | 2023 | 744343 | 0.160 |
Why?
|
Curriculum | 2 | 2021 | 3605 | 0.160 |
Why?
|
Cervix Uteri | 2 | 2019 | 590 | 0.150 |
Why?
|
Peritoneal Neoplasms | 1 | 2023 | 665 | 0.150 |
Why?
|
Endometrial Hyperplasia | 1 | 1997 | 97 | 0.140 |
Why?
|
Intestinal Obstruction | 1 | 2000 | 424 | 0.140 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2010 | 4034 | 0.140 |
Why?
|
Lymph Nodes | 2 | 2016 | 3474 | 0.130 |
Why?
|
Holography | 1 | 2016 | 84 | 0.130 |
Why?
|
Ablation Techniques | 1 | 2018 | 249 | 0.130 |
Why?
|
Progestins | 1 | 1997 | 306 | 0.130 |
Why?
|
Caribbean Region | 1 | 2015 | 194 | 0.130 |
Why?
|
Digestive System Surgical Procedures | 1 | 2000 | 576 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2010 | 9239 | 0.120 |
Why?
|
Genes, BRCA2 | 2 | 2016 | 618 | 0.120 |
Why?
|
Latin America | 1 | 2015 | 381 | 0.120 |
Why?
|
SEER Program | 4 | 2011 | 1508 | 0.120 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2006 | 2026 | 0.120 |
Why?
|
Rwanda | 3 | 2023 | 703 | 0.120 |
Why?
|
Genes, Tumor Suppressor | 1 | 1998 | 1097 | 0.120 |
Why?
|
Uterine Neoplasms | 2 | 2000 | 1513 | 0.110 |
Why?
|
Urology | 1 | 2018 | 399 | 0.110 |
Why?
|
Genetic Counseling | 1 | 2016 | 600 | 0.110 |
Why?
|
Treatment Outcome | 8 | 2019 | 63114 | 0.100 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2015 | 324 | 0.100 |
Why?
|
Staining and Labeling | 1 | 2016 | 1100 | 0.100 |
Why?
|
Germ-Line Mutation | 2 | 2001 | 1788 | 0.100 |
Why?
|
Cancer Care Facilities | 1 | 2014 | 402 | 0.100 |
Why?
|
Brachytherapy | 2 | 2016 | 1248 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 602 | 0.100 |
Why?
|
Electrosurgery | 1 | 1991 | 58 | 0.100 |
Why?
|
Specialization | 1 | 2016 | 777 | 0.100 |
Why?
|
Middle Aged | 17 | 2023 | 213383 | 0.100 |
Why?
|
Cisplatin | 1 | 2016 | 1662 | 0.090 |
Why?
|
Carcinoma | 2 | 2003 | 2375 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2020 | 3798 | 0.090 |
Why?
|
World Health Organization | 1 | 2015 | 1318 | 0.090 |
Why?
|
Early Detection of Cancer | 3 | 2022 | 3086 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11524 | 0.090 |
Why?
|
Menorrhagia | 1 | 2009 | 63 | 0.090 |
Why?
|
Epidemics | 1 | 2014 | 523 | 0.080 |
Why?
|
Antineoplastic Agents | 3 | 2016 | 13695 | 0.080 |
Why?
|
Lymph Node Excision | 2 | 2022 | 1261 | 0.080 |
Why?
|
Surgical Wound Dehiscence | 1 | 2009 | 215 | 0.080 |
Why?
|
Adult | 14 | 2023 | 214055 | 0.070 |
Why?
|
Lymphoma | 1 | 2016 | 1877 | 0.070 |
Why?
|
HIV Infections | 3 | 2020 | 16718 | 0.070 |
Why?
|
Neurofibromatosis 1 | 1 | 2012 | 569 | 0.070 |
Why?
|
Inguinal Canal | 1 | 2005 | 69 | 0.070 |
Why?
|
Specialties, Surgical | 1 | 2011 | 391 | 0.070 |
Why?
|
Clinical Competence | 1 | 2021 | 4687 | 0.070 |
Why?
|
Blood Loss, Surgical | 1 | 2010 | 662 | 0.070 |
Why?
|
Lymphatic Metastasis | 2 | 2022 | 2924 | 0.060 |
Why?
|
Case-Control Studies | 1 | 2023 | 21746 | 0.060 |
Why?
|
Data Collection | 1 | 2014 | 3341 | 0.060 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2020 | 1676 | 0.060 |
Why?
|
Retrospective Studies | 8 | 2023 | 77449 | 0.060 |
Why?
|
Cellulitis | 1 | 2005 | 206 | 0.060 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2003 | 84 | 0.060 |
Why?
|
Genetic Testing | 1 | 2016 | 3444 | 0.060 |
Why?
|
Hysterectomy, Vaginal | 1 | 2003 | 37 | 0.060 |
Why?
|
Cameroon | 1 | 2022 | 71 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2023 | 3479 | 0.050 |
Why?
|
Ultrasonography | 2 | 2015 | 5985 | 0.050 |
Why?
|
Emergencies | 1 | 2009 | 1170 | 0.050 |
Why?
|
Neoplasm Seeding | 1 | 2003 | 87 | 0.050 |
Why?
|
Botswana | 2 | 2016 | 1040 | 0.050 |
Why?
|
Vaginal Neoplasms | 1 | 2003 | 106 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2015 | 3528 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2013 | 57776 | 0.050 |
Why?
|
Paracrine Communication | 1 | 2003 | 277 | 0.050 |
Why?
|
Estrogen Antagonists | 1 | 2001 | 152 | 0.050 |
Why?
|
Ovariectomy | 1 | 2004 | 661 | 0.050 |
Why?
|
Lymphokines | 2 | 2003 | 949 | 0.050 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2003 | 282 | 0.050 |
Why?
|
Genome, Human | 1 | 2014 | 4420 | 0.050 |
Why?
|
Endothelial Growth Factors | 1 | 2003 | 694 | 0.050 |
Why?
|
Aged | 10 | 2016 | 163280 | 0.050 |
Why?
|
Obesity | 1 | 2023 | 12745 | 0.050 |
Why?
|
Survival Analysis | 1 | 2013 | 10252 | 0.050 |
Why?
|
Life Expectancy | 2 | 2004 | 1184 | 0.040 |
Why?
|
Lost to Follow-Up | 1 | 2020 | 105 | 0.040 |
Why?
|
Genotype | 1 | 2014 | 12951 | 0.040 |
Why?
|
Chorionic Gonadotropin, beta Subunit, Human | 1 | 1999 | 73 | 0.040 |
Why?
|
United States | 6 | 2023 | 69872 | 0.040 |
Why?
|
Adenocarcinoma | 2 | 2009 | 6364 | 0.040 |
Why?
|
Human papillomavirus 18 | 1 | 2019 | 128 | 0.040 |
Why?
|
Acyltransferases | 1 | 2020 | 294 | 0.040 |
Why?
|
Lymphedema | 1 | 2005 | 534 | 0.040 |
Why?
|
Prognosis | 5 | 2003 | 29063 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2022 | 709 | 0.040 |
Why?
|
Drug Synergism | 2 | 2020 | 1792 | 0.040 |
Why?
|
Human papillomavirus 16 | 1 | 2019 | 262 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2010 | 3396 | 0.040 |
Why?
|
Estrogen Replacement Therapy | 1 | 2004 | 1203 | 0.040 |
Why?
|
Postoperative Care | 1 | 2004 | 1486 | 0.040 |
Why?
|
Phenotype | 1 | 2014 | 16365 | 0.040 |
Why?
|
Hydatidiform Mole | 1 | 1999 | 279 | 0.040 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 1998 | 221 | 0.040 |
Why?
|
Wnt Proteins | 1 | 2020 | 721 | 0.040 |
Why?
|
Decision Support Techniques | 2 | 2004 | 1956 | 0.040 |
Why?
|
Pregnancy | 4 | 2006 | 29144 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 17446 | 0.030 |
Why?
|
Hormone Replacement Therapy | 1 | 2001 | 745 | 0.030 |
Why?
|
Survival Rate | 3 | 2011 | 12788 | 0.030 |
Why?
|
beta Catenin | 1 | 2020 | 1059 | 0.030 |
Why?
|
Remission Induction | 2 | 1999 | 2386 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2001 | 1683 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2014 | 15519 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1038 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2001 | 20822 | 0.030 |
Why?
|
Forefoot, Human | 1 | 2014 | 32 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2000 | 921 | 0.030 |
Why?
|
Qualitative Research | 1 | 2023 | 2682 | 0.030 |
Why?
|
Socioeconomic Factors | 3 | 2016 | 7785 | 0.030 |
Why?
|
Microspheres | 1 | 2016 | 777 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2019 | 1119 | 0.030 |
Why?
|
Mutation | 2 | 2016 | 29786 | 0.030 |
Why?
|
Chickenpox | 1 | 1994 | 131 | 0.030 |
Why?
|
Interinstitutional Relations | 1 | 2014 | 241 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2003 | 2635 | 0.030 |
Why?
|
Herpesvirus 3, Human | 1 | 1994 | 204 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 2728 | 0.030 |
Why?
|
Capacity Building | 1 | 2014 | 248 | 0.030 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 25043 | 0.030 |
Why?
|
Hospitalization | 1 | 2011 | 10262 | 0.020 |
Why?
|
Infertility, Female | 1 | 1997 | 787 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2016 | 1094 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2019 | 1177 | 0.020 |
Why?
|
Professional Practice Location | 1 | 2011 | 59 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 4456 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2003 | 3703 | 0.020 |
Why?
|
Pedigree | 1 | 1998 | 4644 | 0.020 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39050 | 0.020 |
Why?
|
Advisory Committees | 1 | 2014 | 775 | 0.020 |
Why?
|
Histamine Release | 1 | 1989 | 142 | 0.020 |
Why?
|
Markov Chains | 2 | 2004 | 969 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2000 | 4851 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2020 | 3586 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2012 | 1107 | 0.020 |
Why?
|
Patient Selection | 1 | 2000 | 4215 | 0.020 |
Why?
|
Viral Vaccines | 1 | 1994 | 636 | 0.020 |
Why?
|
Comorbidity | 2 | 2016 | 10388 | 0.020 |
Why?
|
Registries | 1 | 2003 | 8089 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 35421 | 0.020 |
Why?
|
Basophils | 1 | 1989 | 389 | 0.020 |
Why?
|
Plant Proteins | 1 | 1989 | 364 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2003 | 8428 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2009 | 15295 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4479 | 0.020 |
Why?
|
Coronary Disease | 1 | 2001 | 6077 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2020 | 21827 | 0.020 |
Why?
|
Decision Making | 1 | 2000 | 3887 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6895 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6538 | 0.020 |
Why?
|
Lymphocytes | 1 | 1994 | 2617 | 0.020 |
Why?
|
Interleukin-1 | 1 | 1989 | 1263 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2023 | 5137 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2020 | 14557 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 1991 | 1681 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2014 | 2232 | 0.020 |
Why?
|
Neoplasms | 1 | 2014 | 21683 | 0.020 |
Why?
|
Age Factors | 2 | 2004 | 18370 | 0.020 |
Why?
|
Regression Analysis | 2 | 2006 | 6459 | 0.020 |
Why?
|
Male | 3 | 2022 | 350118 | 0.010 |
Why?
|
Adjuvants, Immunologic | 1 | 1989 | 1000 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2020 | 16689 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2020 | 7880 | 0.010 |
Why?
|
Immunoglobulin E | 1 | 1989 | 1463 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2011 | 2453 | 0.010 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 112 | 0.010 |
Why?
|
Dactinomycin | 1 | 2003 | 318 | 0.010 |
Why?
|
Angiopoietin-1 | 1 | 2003 | 114 | 0.010 |
Why?
|
Disease Progression | 1 | 2000 | 13284 | 0.010 |
Why?
|
Risk | 2 | 2006 | 9687 | 0.010 |
Why?
|
Receptor, TIE-2 | 1 | 2003 | 178 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 1994 | 3176 | 0.010 |
Why?
|
Angiopoietin-2 | 1 | 2003 | 173 | 0.010 |
Why?
|
Allergens | 1 | 1989 | 1320 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2003 | 898 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 2001 | 378 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2003 | 772 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9313 | 0.010 |
Why?
|
Probability | 1 | 2006 | 2505 | 0.010 |
Why?
|
Logistic Models | 2 | 2011 | 13408 | 0.010 |
Why?
|
Pericytes | 1 | 2003 | 292 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2003 | 769 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 3508 | 0.010 |
Why?
|
Algorithms | 1 | 2000 | 13881 | 0.010 |
Why?
|
Biopsy | 1 | 1991 | 6756 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2003 | 1547 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2011 | 1797 | 0.010 |
Why?
|
Quality of Life | 1 | 2000 | 12804 | 0.010 |
Why?
|
Time Factors | 2 | 2016 | 40075 | 0.010 |
Why?
|
Stromal Cells | 1 | 2003 | 1355 | 0.010 |
Why?
|
Income | 1 | 2006 | 1913 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81183 | 0.010 |
Why?
|
Risk Factors | 1 | 2003 | 72290 | 0.010 |
Why?
|
Family Health | 1 | 2001 | 1282 | 0.010 |
Why?
|
Laparotomy | 1 | 1999 | 473 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 12354 | 0.010 |
Why?
|
CA-125 Antigen | 1 | 1998 | 286 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2003 | 1660 | 0.010 |
Why?
|
Cohort Studies | 2 | 2011 | 40561 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2003 | 3772 | 0.010 |
Why?
|
Chickenpox Vaccine | 1 | 1994 | 79 | 0.010 |
Why?
|
Postmenopause | 1 | 2001 | 2461 | 0.010 |
Why?
|
Vaccines, Attenuated | 1 | 1994 | 342 | 0.010 |
Why?
|
Animals | 2 | 2020 | 168757 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 2003 | 3768 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2003 | 3508 | 0.010 |
Why?
|
Poaceae | 1 | 1989 | 25 | 0.010 |
Why?
|
Pollen | 1 | 1989 | 75 | 0.010 |
Why?
|
Antigens, Plant | 1 | 1989 | 86 | 0.010 |
Why?
|
Health Promotion | 1 | 2001 | 2205 | 0.010 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1989 | 370 | 0.010 |
Why?
|
Reoperation | 1 | 1999 | 4201 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2001 | 5391 | 0.010 |
Why?
|
Medicare | 1 | 2006 | 6566 | 0.010 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1989 | 349 | 0.000 |
Why?
|
RNA, Messenger | 1 | 2003 | 13033 | 0.000 |
Why?
|
Immunity, Cellular | 1 | 1994 | 1607 | 0.000 |
Why?
|
Models, Biological | 1 | 2003 | 9583 | 0.000 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 3870 | 0.000 |
Why?
|
Analysis of Variance | 1 | 1994 | 6365 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1999 | 12959 | 0.000 |
Why?
|
Lymphocyte Activation | 1 | 1994 | 5524 | 0.000 |
Why?
|
Recombinant Proteins | 1 | 1989 | 6622 | 0.000 |
Why?
|
Infant | 1 | 1994 | 35136 | 0.000 |
Why?
|
Child, Preschool | 1 | 1994 | 41006 | 0.000 |
Why?
|
Child | 1 | 1994 | 77709 | 0.000 |
Why?
|
Adolescent | 1 | 1994 | 85781 | 0.000 |
Why?
|